Palatin Technologies Inc (PTN) Stock Analysis

Verdict: AVOID

Severe cash burn and a remaining runway under two months mandate impending equity dilution, overshadowing pipeline progress.

Investment score: 22/100

Analysis as of 2026-09-17

Is Palatin Technologies Inc stock worth reviewing? AI model thesis

The model views PTN as a high-risk microcap biotech facing an immediate liquidity bottleneck that makes equity dilution virtually inevitable.

7-factor investment score

Valuation: 30/100 (weight 20%)
Financial Health: 5/100 (weight 15%)
Technical Momentum: 20/100 (weight 15%)
Earnings Quality: 25/100 (weight 15%)
Insider Sentiment: 20/100 (weight 10%)
Analyst Consensus: 40/100 (weight 10%)
Risk-Adjusted Return: 15/100 (weight 15%)

Palatin Technologies Inc opportunities and risks

What speaks for PTN

Obesity Pipeline Synergy (Bremelanotide + Tirzepatide)

What speaks against PTN

Existential Cash Runway Crisis and Impending Equity Dilution

Peers and competitors

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
PTN	n/a	1.4x	n/a	99.8%	-48.5%	-83.9%
BCDA	n/a	0.0x	n/a	0.0%	0.0%	-43.9%
ALLR	n/a	55.8x	n/a	107.5%	-3575.1%	-71.6%
ACUT	n/a	21.3x	n/a	100.0%	-1680.0%	-57.6%
AKTX	n/a	0.0x	n/a	0.0%	0.0%	-92.3%
KTTA	n/a	0.0x	1959.0x	0.0%	0.0%	-111.5%
Peer median	n/a	0.0x	n/a	0.0%	0.0%	-71.6%

Frequently asked questions about Palatin Technologies Inc (PTN)

Is PTN stock a good investment?

The cached TradeMates AI model rates Palatin Technologies Inc as AVOID with an investment score of 22/100. The model views PTN as a high-risk microcap biotech facing an immediate liquidity bottleneck that makes equity dilution virtually inevitable. This is algorithmic model output, not personal investment advice.

Is PTN stock a buy?

The TradeMates model verdict for PTN is AVOID with an investment score of 22/100. Treat this as a model signal to review, not a personal buy recommendation.